DOI: 10.1002/cam4.4172

RESEARCH ARTICLE

Cancer Medicine WILEY

Cabazitaxel multiple rechallenges in metastatic castrationresistant prostate cancer

Cedric Pobel¹ | Edouard Auclin¹ | Diego Teyssonneau² | Brigitte Laguerre³ | Mathilde Cancel⁴ | Elouen Boughalem⁵ | Johanna Noel¹ | Pierre Emmanuel Brachet⁶ | Denis Maillet⁷ | Philippe Barthelemy⁸ | Carole Helissey⁹ | Constance Thibault¹ | Stéphane Oudard¹

¹Oncology Department, Hôpital Européen Georges Pompidou, AP-HP, University of Paris, Paris, France

²Oncology Department, Bergonié Institut, Bordeaux, France

³Oncology Department, Eugène Marquis Center, Rennes, France

⁴Oncology Department, University hospital of Tours, France

⁵Oncology Department, Institut de Cancérologie de l'Ouest, Angers, France

⁶Oncology Department, Centre François Baclesse, Caen, France

⁷Oncology Department, University hospital of Lyon, France

⁸Medical Oncology, University Hospital Strasbourg / Institut de Cancérologie Strasbourg Europe, Strasbourg, France ⁹Clinical Research Unit, Military Hospital Begin, Saint Mandé, France

Correspondence

Cedric Pobel, Oncology department, European Georges Pompidou Hospital, 20 rue Leblanc, 75015, Paris, France. Email: cedric.pobel@gmail.com

Abstract

Introduction: Cabazitaxel multiple rechallenges may be a treatment option in heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC) who had a good initial response to cabazitaxel and who are still fit to receive it. Our objective was to assess the efficacy and toxicity of multiple rechallenges.

Patients and methods: We retrospectively identified 22 mCRPC patients previously treated with docetaxel and/or androgen receptor-targeted agents who received multiple cabazitaxel rechallenges in 9 French centers. Cabazitaxel was initiated at a dose of 25 mg/m² q3week. A reduced dose (20 mg/m² q3w) or an alternative schedule (mainly 16 mg/m^2 q2w) was increasingly used for subsequent rechallenges. Progression-free survival, prostate-specific antigen (PSA) response, best clinical response, and grade \geq 3 toxicities were collected. Overall survival was calculated from various time points.

Results: Twenty-two patients with an initial response to cabazitaxel were rechallenged at least twice. The median number of cabazitaxel cycles was 7 at first cabazitaxel treatment, 6 at first rechallenge, and 5 at subsequent rechallenges. Median progression-free survival at first rechallenge was 9.6 months and 5.6 months at second rechallenge. Median overall survival was 50.9 months from the first cabazitaxel dose, 114.9 months from first life-extending therapy initiation in mCRPC, and 105 months from mCRPC diagnosis. There was no cumulative grade \geq 3 neuropathy or nail disorder and one case of febrile neutropenia.

Conclusion: Cabazitaxel multiple rechallenges may be a treatment option without cumulative toxicity in heavily pretreated patients having a good response to first cabazitaxel use and still fit to receive it.

Cedric Pobel and Edouard Auclin participated equally in the work.

Constance Thibault and Stéphane Oudard coordinated the work.

_____ This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

WILEY

Novelty & Impact Statements: Patients with metastatic castration-resistant prostate cancer can be treated with Cabazitaxel after docetaxel and androgen receptor-targeted agent. This chemotherapy can be used multiple times with efficacy and manageable toxicity.

KEYWORDS

prostate cancer, chemotherapy, metastasis, cancer management, urological oncology

1 | INTRODUCTION

Since 2004, several agents have shown an overall survival (OS) benefit in metastatic castration-resistant prostate cancer (mCRPC) patients, including in chronological order docetaxel, sipuleucel-T cabazitaxel, abiraterone acetate, enzalutamide, radium-223, and olaparib.^{1,2} Cabazitaxel use is restricted to patients previously treated with docetaxel,^{3,4} olaparib use is restricted to patients with BRCA1/2 mutations previously treated with an androgen receptor-targeted agent (ARTA)² and there is now level 1 evidence that patients who have progressed with a first ARTA poorly respond to another ARTA.^{2,5,6} Treatment options in mCRPC are thus limited.

Cabazitaxel is a next-generation taxane that retains its activity in mCRPC patients progressing on docetaxel³ or ARTA.⁶⁻⁸ In the prospective CARD trial, cabazitaxel significantly improved radiographic progression freesurvival (PFS) and OS versus abiraterone or enzalutamide in mCRPC patients who had received docetaxel and progressed within 12 months with the alternative ARTA.⁶ Two large retrospective registries conducted by our institution in daily life suggested that a treatment sequence including docetaxel, one ARTA, and cabazitaxel provided an optimal OS.^{9,10} The main toxicity of cabazitaxel is the risk of neutropenia which can be effectively prevented by G-CSF prophylaxis from the first cycle.⁶ Compared to docetaxel, cabazitaxel also shows a reduced incidence of alopecia, peripheral neuropathy, peripheral edema, and nail disorders with less cumulative toxicity.^{4,11} Rechallenge with cabazitaxel could thus be an interesting option for mCRPC patients having exhausted available life-extending therapies.

Here, we report the efficacy and toxicity of multiple cabazitaxel rechallenges in heavily pretreated mCRPC patients in daily practice.

2 | MATERIALS AND METHODS

2.1 | Setting and design

We retrospectively reviewed clinical data of 710 consecutive mCRPC patients treated with cabazitaxel in nine French centers from February 2012 to July 2020. Of them, 22 were rechallenged at least twice with cabazitaxel.

Disease history was collected for each patient. The activity of each cabazitaxel treatment line was measured by prostate-specific antigen (PSA) response \geq 50% from baseline, best clinical benefit (as per investigator judgment based on European Cooperative Oncology Group performance status [ECOG-PS], pain, and analgesic consumption), radiological and/or clinical PFS. OS was calculated from mCRPC diagnosis, from initiation of first life-extending therapy, first cabazitaxel treatment, and each cabazitaxel rechallenge. Progressive disease was defined by two on the three following criteria of the Prostate Cancer Clinical Trials Working Group (PCWG2): Radiological progression according to RECIST 1.1, PSA rising $\ge 25\%$ or clinical progression. Grade ≥ 3 toxicities according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5 were collected. Follow-up for all deceased patients was complete until the time of their death.

2.2 | Ethics

This study received Ethics Committee approval. Patients still alive gave their written consent and confidentiality approval was obtained from the Commission Nationale de l'Informatique et des Libertés (CNIL).

2.3 Data analyses

Analyses were descriptive and conducted using the R^{*} software version 3.6.1. OS and PFS were estimated by the Kaplan–Meier method.

3 | RESULTS

3.1 | Patient characteristics

Median follow-up from mCRPC diagnosis for the 22 mCRPC patients rechallenged with cabazitaxel was

6306

WILEY-Cancer Medicine

94.7 months. Almost all patients had received docetaxel and at least one ARTA before cabazitaxel initiation (Figure 1). Treatment sequence did not include sipuleucel T, radium-223 or olaparib because these therapies are not reimbursed in France. Cabazitaxel was initiated in thirdline setting or beyond in 17 patients (77.3%). Clinical characteristics are provided in Table 1.

3.2 | Cabazitaxel treatment

Patients rechallenged with cabazitaxel were good responders to first cabazitaxel use, in terms of PSA response, clinical benefit, and PFS (Table 2). Overall patients received a median number of 19.5 cabazitaxel cycles (7 at first use, 6 at first rechallenge, and 5 at subsequent rechallenges). In most cases, cabazitaxel was initiated at a dose of 25 mg/m² every 3 weeks but a reduced dose (20 mg/m² every 3 weeks) or an alternative schedule (mainly 16 mg/ m² every 2 weeks) was increasingly used for subsequent rechallenges. Median cabazitaxel-free interval decreased with subsequent rechallenges. Most patients received prophylactic G-CSF.

A clinical benefit measured at its best was observed in 50% and 45% of patients at first and second rechallenges. A PSA decrease of at least 60% was observed at first, second, and third cabazitaxel rechallenges.

Median PFS was 11.8 months at first cabazitaxel use. 9.6 months at first rechallenge, and 5.6 months at second rechallenge. Median OS reached 105 months from mCRPC diagnosis, 114.9 months from first lifeextending therapy, 50.9 months from first cabazitaxel use, 43.5 months from the first rechallenge, 24.8 months from the second rechallenge, and 19.2 months from the third rechallenge. The median number of cycles received was 7 (4 to 12), 6 (3 to 16), 5 (1 to 12), 5 (3 to 12), and 5 at first, second, third, fourth, and fifth use of cabazitaxel, respectively. The reason for treatment discontinuation was the completion of the predefined number of cabazitaxel cycles for most of the patients: 95.5% of them at first use, 81.8% of them at second use, 45% of them at third use, and 50% of them at fourth use. Progressive disease caused discontinuation in 4.5% of cases at second use, 45% of cases at third use, and 25% of cases at fourth use. Toxicity \geq grade 3 was found to cause treatment discontinuation for only one patient at second and fourth use.

The toxicity of cabazitaxel was manageable with only one case of febrile neutropenia during the second rechallenge. Six patients experienced grade ≥ 3 adverse events during the first or second rechallenge (hematuria, n = 3; cholestasis n = 1, diarrhea, n = 1, febrile neutropenia, n = 1). No grade ≥ 3 neuropathy or alopecia or nail disorders was reported.




FIGURE 1 Swimmer plot summarizing treatment strategies from the diagnosis of mCRPC for each patient rechallenged with cabazitaxel. mCRPC: metastatic castration-resistant prostate cancer

POBEL ET AL.	Cancer Medicine	-WILEY
TABLE 1 Clinical characteristics of22 mCRPC patients rechallenged withcabazitaxel	Characteristics	No. (%)
	Total number of patients	22
	Median age at first treatment initiation (range), years	60 (52–78)
	Gleason score 8–10 at diagnosis, n (%)	12 (57.1)
	Median follow-up from mCRPC diagnosis, months	94.7
	Characteristics at cabazitaxel initiation	
	Metastatic sites (Halabi classification), n (%)	
	Lymph node only	0
	Bone (+/- lymph nodes)	19 (86.4)
	Visceral (+/- bone, +/- lymph nodes)	3 (13.6)
	ECOG PS 0–1, n (%)	19 (86.4)
	Pain, n (%)	13 (59.1)
	Consumption of narcotic analgesics, n (%)	6 (27.3)
	Biology	
	Median PSA, ng/ml	85.7
	Median hemoglobin, g/dl	12.0
	Median neutrophil to lymphocyte ratio	3.3
	LDH >ULN, n (%)	2 (22.2)
	ALP >ULN, n (%)	5 (50)

Abbreviations: ALP, Alkaline phosphatase; ECOG-PS, European Cooperative Oncology Group performance status; LDH, Lactate dehydrogenase; mCRPC, metastatic castration-resistant prostate cancer; PSA, prostate-specific antigen.

4 DISCUSSION

This is, to our knowledge, the first report of multiple cabazitaxel rechallenges in mCRPC patients treated in daily practice. Key findings of our research are those good responders to the first use of cabazitaxel, even when heavily pretreated, may be rechallenged several times with cabazitaxel with a good response to therapy and without evidence of cumulative toxicity. Indeed, in those 22 mCRPC patients analyzed, we showed a median PFS of 9.6 months and 5.6 months and a disease control rate of 100% and 77.3% at first and second cabazitaxel rechallenge, respectively. OS calculated from first life-extending therapy and mCRPC diagnosis reached 114.9 and 105 months, respectively. The most common grade \geq 3 adverse events was the occurrence of hematuria (three patients) and one patient reported febrile neutropenia. There was no cumulative grade \geq 3 peripheral neuropathy or nail disorder.

Our results further support those previously reported by Thibault et al in 69 mCRPC patients well responding to cabazitaxel and rechallenged once with the same drug.¹² Median PFS with cabazitaxel rechallenge was 7.8 months and a best clinical benefit which was improved in 34.3% and stable in 47.8% of cases. Median OS calculated from the first life-extending therapy and from mCRPC diagnosis

reached 59.9 months and 78.3 months, respectively. No cumulative toxicity was reported.

We previously reported that docetaxel could be rechallenged in mCRPC patients having a good initial response.¹³ However, docetaxel rechallenge is associated with a cumulative incidence of peripheral neuropathy, nail disorders, and asthenia/fatigue which is bothersome for the patients. Moreover, there is increasing evidence that docetaxel may lose activity in patients previously treated with ARTA.^{7,9} This may be due to a restauration of androgens in microenvironment after ARTA was found because of all the mechanisms of resistance restoring androgen resulting in tumor progression. This androgen level in microenvironment could explain docetaxel lost of activity due to difficulties for tumoral penetration.¹⁴ Cabazitaxel shows a greater intra-tumoral penetration than docetaxel¹⁵ and has been shown in preclinical models and prospective clinical studies to retain its activity in patients who have progressed with ARTA.^{6,8}

Retrospective design with a small sample of patients is the main limitation of our study. It is also important to note that patients analyzed were highly selected since they were good responders to cabazitaxel initial treatment and were fit enough to be rechallenged with it. Nonetheless, our results are promising and should be confirmed by prospective clinical studies.

WILEY-Cancer Medicine

TABLE 2 Efficacy and toxicity of each cabazitaxel treatment in 22 mCRPC patients rechallenged with cabazitaxel

Patient (N)(n = 22)(n = 22)(n = 2)(n = 3)(n = 5)(n = 5)Calculate initial dose, N (%)2 sing/m ² q ³ w16 (72.7)8 (36.4)2 (9.1)1 (20)00 ng/m ² q ³ w3 (13.6)5 (22.7)10 (45.5)1 (20)01 ong/m ² q ² w3 (13.6)9 (40.9)1 (4.5)000Median number of cycles, N7 (4-12)6 (3-16)5 (1-12)5 (3-12)5 (3Torphylactic O-SFF, N(%)1 (63.6)1 (8 (8.18)17 (7.7)4 (80)1Best elimital benefit, N(%)Improved11 (50)11 (50)1 (14.5)1 (20)1Stable10 (45.5)1 (150)7 (31.8)4 (80)0Jorse control rate1 (20,5)1 (20,1)1 (20,1)1Jorgense (%)Jorgense (%) <td co<="" th=""><th></th><th>First use</th><th>Second use</th><th>Third use</th><th>Fourth use</th><th>Fifth use</th></td>	<th></th> <th>First use</th> <th>Second use</th> <th>Third use</th> <th>Fourth use</th> <th>Fifth use</th>		First use	Second use	Third use	Fourth use	Fifth use	
25 mg/m²q3w16(72.7)8(36.4)2(9.1)1(20)020 mg/m²q3w3(13.6)5(22.7)10(45.5)1(20)016 mg/m²q2w3(13.6)9(40.9)9(40.9)3(60)110 mg/m²wekly001(45.5)000Media number of cycles, N7(4-12)8(3.6)5(1-12)5(3-12)5Prophylactic G-SF, N(%)14(6.3)18(8.18)7(7.3)4(80)1Best clinical benefit, N(%)11(50)10(45.5)1(20)1Stable10(45.5)11(50)7(31.8)4(80)0Norse14(5.5)10(50.5(22.7)00Joase control rate19(8.6)11(50)7(73.3)5(10)1Norse19(8.6)14(6.3.6)12(60)4(80)0Post response (%)189.65.610.29.1Stoff or each line start110.410.29.1Ig5% C1]0.914.513.513.7NR]8.3NR]1Ig5% C1]0.914.5N10.4S10.211Ig5% C1]0.914.5N10.4S1.011Ig5% C1]0.914.5N10.4S1.011Ig5% C1]0.914.5N10.4S1.011Ig5% C1]0.91.4S1.01.011Ig5% C1]0.91.4S1.01.011Ig5% C1]0.91.4S <th>Patient (N)</th> <th></th> <th></th> <th></th> <th></th> <th>(n = 1)</th>	Patient (N)					(n = 1)		
20 m/m² q3w3(13.6)5(22.7)10 (45.5)1(20)016 mg/m² q2w3(13.6)9(40.9)9(40.9)3(60)110 mg/m² wekly001(4.55)00Median number of cycles, N (range)7(4-12)6(3-16)5(1-12)5(3-12)5Prophylactic G-CSF, N(%)14(63.6)18 (81.8)17(77.3)4(80)1Bert-Unical benefit, N(%)11 (50)10 (45.5)1 (20)1Improved11 (50)11 (50)7 (31.8)4 (80)0Stable10 (45.5)1 (20)7 (31.8)4 (80)0Worse1 (45.5)2 (200)7 (31.8)4 (80)0Post secontrol rate1 (45.5)1 (63.6)1 (20)00Post secontrol rate1 (86.4)1 (20)000Post secontrol rate1 (86.4)1 (20)000Post Secontrol rate1 (84.5)1 (20)000Post Secontrol rate1 (84.5)1 (3.5)1 (20)00Post CI90.43.524.81 (20)00Post CI1 (45.5)1 (45.5)1 (45.5)1 (20)00Post CI1 (95.5)1 (81.8)1 (45.5)1 (20)00Post CI1 (45.5)1 (45.5)1 (45.5)1 (20)00Post CI1 (45.5)1 (45.5)1 (45.5)1 (20)00Post CI1 (45.5)1 (45.	Cabazitaxel initial dose, N (%)							
1 mm/m ² q2w3 (13.6)9 (40.9)9 (40.9)3 (60)110 mg/m ² weekly001 (4.55)00Median number of cycles, N (range)7 (4-12)6 (3-16)5 (1-12)5 (3-12)5Proplactic G-CSF, N(%)1 (8.0)1 8 (81.8)1 7 (77.3)4 (80)1Best clinical benefit, N (%)1 (150)1 (150)1 (045.5)1 (200)1Stable10 (45.5)11 (50)7 (31.8)4 (80)0Øvorse1 (4.5)05 (22.7)000Disease control rate21 (95.5)22 (100)17 (77.3)5 (100)1PS Form each line start55%19 (86.4)14 (63.6)12 (60)4 (80)0PS Form each line start9.65.610.29.1[95% CI]0.94.52.61.49.29.1[95% CI]0.94.52.4819.29.1[95% CI]6.93.52.4819.29.1[95% CI]14.5-NR2.69-NR]13.7-NR]8.3-NR]10.1Predefined number of courses21 (95.5)18 (81.8)10 (45.5)1.20010Progression014.5-NR]2.69-NR]12.7-NR]2.6001.20010Imprined ECOG PS1 (4.5)18 (81.8)10 (45.5)1.20001.20010Tractity compression01 (4.5)1 (4.5)01 (201)01.2001.2001.2001.20	$25 \text{ mg/m}^2 \text{q}3\text{w}$	16 (72.7)	8 (36.4)	2 (9.1)	1 (20)	0		
10 mg/m² weekly001 (4.5)00Median number of cycles, N (range)7 (4-12)6 (3-16)5 (1-12)5 (3-12)5Prophylactic G-CSF, N(%)1 (60.5)1 8 (81.8)7 (77.3)4 (80)1Best-clinical benefit, N(%)1<50010 (45.5)1 (20)1Improved11 (50)10 (45.5)1 (50)1 (20,0)1Stable10 (45.5)1 (50)7 (31.8)4 (80)0Worse1 (4.5)05 (22.7)000Disease control rate12 (95.5)2 (100)17 (77.3)5 (100)1S5%19 (86.4)14 (63.6)12 (60)4 (80)0PFs from each line start9.65.610.29.1[957 CT][9 -14.2][26.9-NR][13.7-NR][8.3-NR]7Overall survival from each lines20.93.52.4819.2-[955 CT]6.93.52.4819.2[955 CT]6.98.61.2.2]13.7-NR][8.3-NR]Predefined number of courses21 (95.5)18 (81.8)10 (45.5)1 (20)00[970 regession01 (4.5)2 (9.1)1 (20)00Impared ECOG PS14 (4.5)2 (9.1)2 (9.1)1 (20)00[970 regession01 (4.5)01 (20)00[970 regession01 (4.5)03 (20)00 <td>$20 \text{ mg/m}^2 \text{ q}3\text{w}$</td> <td>3 (13.6)</td> <td>5 (22.7)</td> <td>10 (45.5)</td> <td>1 (20)</td> <td>0</td>	$20 \text{ mg/m}^2 \text{ q}3\text{w}$	3 (13.6)	5 (22.7)	10 (45.5)	1 (20)	0		
Median number of cycles, N (range)7(4-12)6(3-16)5(1-12)5(3-12)5Prophylactic G-CSF, N (%)14 (63.6)18 (81.8)17 (77.3)4 (80)1Best clinical benefit, N (%)11 (50)11 (50)10 (45.5)1 (20)1Improved11 (50)11 (50)10 (45.5)1 (20)1Stable10 (45.5)11 (50)7 (31.8)4 (80)0Worse14 (4.5)05 (22.7)000Disease control rate19 (86.4)14 (63.6)12 (60)4 (80)0PSA response (%)≥50%19 (86.4)14 (63.6)12 (60)4 (80)0PSF from each line start11.89.65.610.29.1[95% CI][9-14.2][8.6-12.2][4.2-9][7-NR]-Median (months)11.89.65.610.29.1[95% CI][9-14.2][26.9-NR][13.7-NR][8.3-NR]-Predefined number of courses20.913.810 (45.5)12.001[95% CI](21.95.5)18 (81.8)10 (45.5)12.000Improved fine quimber of courses14.55.513.8(18.9)10 (45.5)12.000Improved fine quimber of courses14.55.513.8(18.9)10 (45.5)12.000Improved fine quimber of courses14.55.513.8(18.9)10 (45.5)12.000Improved fine quimber of courses14.55.513.8(18.9)10.45.5 <th< td=""><td>$16 \text{ mg/m}^2 \text{ q}2\text{w}$</td><td>3 (13.6)</td><td>9 (40.9)</td><td>9 (40.9)</td><td>3 (60)</td><td>1</td></th<>	$16 \text{ mg/m}^2 \text{ q}2\text{w}$	3 (13.6)	9 (40.9)	9 (40.9)	3 (60)	1		
(range)It was a series of the s	10 mg/m ² weekly	0	0	1 (4.55)	0	0		
Best clinical benefit, N (%) Inproved 11 (50) 11 (50) 10 (45.5) 1 (20) 1 Stable 10 (45.5) 11 (50) 7 (31.8) 4 (80) 0 Worse 1 (4.5) 0 5 (22.7) 0 0 Disease control rate 21 (95.5) 22 (100) 17 (7.3) 5 (100) 1 PSA response (%) ≥50% 19 (86.4) 14 (63.6) 12 (60) 4 (80) 0 PS from each line start Median (months) 11.8 9.6 5.6 10.2 9.1 [95% CI] [9-14.2] [8.6-12.2] [4.2-9] [7-NR] - [95% CI] [9.4.5-NR] [26.9-NR] [13.7-NR] [8.3-NR] - Predefined number	-	7 (4–12)	6 (3-16)	5 (1-12)	5 (3-12)	5		
Improved11 (50)11 (50)10 (45.5)10 (45.5)10 (45.5)10 (45.7)	Prophylactic G-CSF, N (%)	14 (63.6)	18 (81.8)	17 (77.3)	4 (80)	1		
Stable10 (45.5)11 (50)7 (31.8)4 (80)0Worse1 (4.5)05 (22.7)000Disease control rate2 (100)17 (77.3)5 (100)1 > Som 2 (105.5)2 (2100)17 (77.3)5 (100)0 > Som sersense (%) 1 (46.3.6)12 (60.0)4 (80.0)0 > Som sec (%) 1 (46.3.6)12 (60.0)4 (80.0)0 P SF rom each line start 5.610.29.1Median (months)10.89.65.610.29.1[95% CI](9-14.2)(8.6-12.2)(4.2-9)(7.NR]9.1Median (months)50.943.524.819.29.1[95% CI]60.912 (69-NR]11.3.7-NR](8.3-NR]10.4Predefined number of courses14 (53.0)10 (453.0)12.001Predefined number of courses14 (9.5)18 (81.8)10 (453.0)12.001Impaired ECOG PS14.5.52 (9.1)10.45.110.20.110Impaired ECOG PS14.5.56.97.28.69.51<.001Impaired ECOG PS9.56.97.28.69.51<.0011Median in month (range)2.56.00(16-41.5)(3.7-20.6)1Median in month (range)2.36.00(16-41.5)(3.7-20.6)Median in month (range)2.36.00(16-41.5)(3.7-20.6) <td>Best clinical benefit, N (%)</td> <td></td> <td></td> <td></td> <td></td> <td></td>	Best clinical benefit, N (%)							
Worse Disease control rate1 (4.5) 2 (95.5)05 (22.7) 5 (100)00PSA response (%)22 (100)17 (77.3)5 (100)1≥50%19 (86.4)14 (63.6)12 (60)4 (80)0PFS from each line start9.65.610.29.1[95% CI](9-14.2)[8.6-12.2][4.2-9](7-NR]9.1(95% CI](9-14.2)[26.9-NR][13.7-NR][8.3-NR]Overall survival from each line startMedian (months)50.943.524.819.2[95% CI](44.5-NR][26.9-NR](13.7-NR][8.3-NR]Predefined number of courses21 (95.5)18 (81.8)10 (45.5)2 (40)1Progression014.45.72 (9.1)2 (9.1)1 (20)0Impaired ECOG PS14.5.52 (9.1)2 (9.1)1 (20)0Toxicity01 (4.5)01 (20)0Median in month (range)9.56.97.28.6Median in month (range)(2.3-56.0)(1.6-41.5)(3.7-20.6)Toxicity ≥grade 3 (N)Toxicity ≥grade 3 (N)	Improved	11 (50)	11 (50)	10 (45.5)	1 (20)	1		
Disease control rate21 (95.5)22 (100)17 (77.3)5 (100)1PSA response (%)19 (86.4)14 (63.6)12 (60)4 (80)0PST om each line start11.89.65.610.29.1Median (months)[9-14.2][8.6-12.2][4.2-9][7-NR]9.1PST or user visual from each line start12.210.2[7-NR]9.1Median (months)[0.9.4][8.6-12.2][4.2-9][9.2 (N]9.1Median (months)[0.9.4][2.69.NR][1.3.7NR][9.2 (N]9.1Predefined number of courses14.5[8.81.8]10.4(5.3)[8.3.NR]11.3Progression[1.69.5][1.81.8][0.45.3][1.61.5][1.61.5][1.61.5]Impaired ECOG PS[1.61.5][1.61.5][0.41.5][1.61.5][Stable	10 (45.5)	11 (50)	7 (31.8)	4 (80)	0		
PSA response (%) $\geq 50\%$ 19 (86.4)14 (63.6)12 (60)4 (80)0PFS from each line startMedian (months)11.89.65.610.29.1[95% CI][9-14.2][8.6-12.2][4.2-9][7-NR] $-$ Overall survival from each line startMedian (months)50.943.524.819.2 $-$ [95% CI][44.5-NR][26.9-NR][13.7-NR][8.3-NR] $-$ Predefined number of courses21 (95.5)18 (81.8)10 (45.1)2 (40.0)1Progression014.5.010 (45.1)1 (20.0)01Impaired ECOG PS14.5.12 (9.1)1 (20.0)01Toxicity01 (4.5.1)01 (20.0)0Median in month (range)(2.3-56.0)(16-41.5)(3.7-20.6) $ -$	Worse	1 (4.5)	0	5 (22.7)	0	0		
≥50%19 (86.4)14 (63.6)12 (60)4 (80)0FF from each line startMedian (months)11.89.65.610.29.1[95% CI][9-14.2][8.6-12.2][4.2-9][7-NR]-Median (months)50.943.524.819.2-[95% CI]60.943.513.7-NR][8.3-NR]-[95% CI](44.5-NR][26.9-NR]10.45[8.3-NR]-Predefined number of courses21 (95.5)18 (81.8)10 (45.5)2 (40.0)1Progression014.5.310 (45.5)1 (20.0)0[mpaired ECOG PS14 (45.5)2 (9.1)2 (9.1)1 (20.0)0Toxicity01 (4.5.5)01 (20.0)00[mpaired ECOG PS01 (4.5.5)01 (20.0)00[mpaired ECOG PS03.56.97.28.69.59.51 (4.5.15)<	Disease control rate	21 (95.5)	22 (100)	17 (77.3)	5 (100)	1		
From each line startMedian (months)11.89.65.610.29.1[95% CI][9-14.2][8.6-12.2][4.2-9][7-NR]-Median (months)50.94.3.524.819.2-[95% CI][44.5-NR][26.9-NR][13.7-NR][8.3-NR]-Predefined number of courses19.1010.1010.1010.10[Progression014.5010.4502.04010[mpaired ECOG PS14.502.01.010.20.000[Toxiciy014.5001.20.000[Pretersineneeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeee	PSA response (%)							
Median (months)11.89.65.610.29.1[95% CI][9-14.2][8-6-12.2][4.2-9][7-NR][- Hedian (months) 50.94.3.524.819.2[95% CI][44.5-NR][26.9-NR][13.7-NR][8.3-NR]Predefined number of courses21 (95.5)18 (81.8)10 (45.5)2 (40.0)1Progression014.510 (45.5)10 (45.5)000Impaired ECOG PS1 (4.5)2 (9.1)1 (20.0)00Toxicity01 (4.5)01 (20.0)00Present user9.56.97.28.6Median in month (range)(2.3-56.0)16-41.5)(3.7-20.6)Curvity Serder 3(N)	≥50%	19 (86.4)	14 (63.6)	12 (60)	4 (80)	0		
[95% CI][9-14.2][8.6-12.2][4.2-9][7-NR]— <i>BBB</i> <td>PFS from each line start</td> <td></td> <td></td> <td></td> <td></td> <td></td>	PFS from each line start							
Overall survival from each line statute 50.9 43.5 24.8 19.2 [95% CI] [44.5-NR] [26.9-NR] [13.7-NR] [8.3-NR] Predefined number of courses 21 (95.5) 18 (81.8) 10 (45) 2 (40) 1 Progression 0 1 (4.5) 10 (45) 1 (20) 0 Impaired ECOG PS 1 (4.5) 2 (9.1) 2 (9.1) 1 (20) 0 Toxicity 0 1 (4.5) 0 1 (20) 0 Median in month (range) (2.3-56.0) (1.6-41.5) (3.7-20.6) Toxicity ≥grade 3 (N)	Median (months)	11.8	9.6	5.6	10.2	9.1		
Median (months)50.943.524.819.2 $ [95\% CI]$ $(44.5 \cdot NR)$ $[26.9 \cdot NR)$ $[13.7 \cdot NR)$ $[8.3 \cdot NR]$ Fordiscontinuation NU Predefined number of courses21 (95.5) $18 (81.8)$ $10 (45.5)$ $2 (40.0)$ 1 $[Progression$ 0 $1(4.5)$ $10 (45.5)$ $10 (45.5)$ 0 1 $[mpaired ECOG PS$ $1(4.5)$ $2(9.1)$ $2(9.1)$ $1(20.0)$ 0 $[Toxiciy$ 0 $1(4.5)$ 0 $1(20.0)$ 0 $Progression01(4.5)01(20.0)0[mpaired ECOG PS01(4.5)01(20.0)0[Toxiciy001(4.5)01(20.0)0Progression01(4.5)01(20.0)0[mpaired ECOG PS00000[mpaired ECOG PS00000Progression00000Progression00000Progression00000Progression00000Progression00000Progression00000Progression00000Progression00$	[95% CI]	[9-14.2]	[8.6-12.2]	[4.2–9]	[7-NR]	_		
[95% CI] [44.5-NR] [26.9-NR] [13.7-NR] [8.3-NR] F edefined number of courses 21 (95.5) 18 (81.8) 10 (45.0) 2 (40.0) 1 Progression 0 14.5.0 10 (45.0) 1 (20.0) 0 Impaired ECOG PS 1 (4.5.0) 2 (9.1.0) 1 (20.0) 0 Toxicity 0 1 (4.5.0) 0 0 0 Preserval between course 9.5 6.9 7.2 8.6 Median in month (range) (2.3-56.0) (16-41.5) (3.7-20.6)	Overall survival from each line start							
Reason for discontinuation, N (%) Predefined number of courses 21 (95.5) 18 (81.8) 10 (45) 2 (40) 1 Progression 0 1 (4.5) 10 (45) 1 (20) 0 Impaired ECOG PS 1 (4.5) 2 (9.1) 2 (9.1) 1 (20) 0 Toxicity 0 1 (4.5) 0 1 (20) 0 Free interval between cabazitaxel-line use 9.5 6.9 7.2 8.6 Median in month (range) (2.3-56.0) (1.6-41.5) (3.7-20.6) Toxicity ≥grade 3 (N) 5 5 5 5 5 5 5 5 5	Median (months)	50.9	43.5	24.8	19.2	—		
Predefined number of courses 21 (95.5) 18 (81.8) 10 (45) 2 (40) 1 Progression 0 1 (4.5) 10 (45) 1 (20) 0 Impaired ECOG PS 1 (4.5) 2 (9.1) 2 (9.1) 1 (20) 0 Toxicity 0 1 (4.5) 0 1 (20) 0 Free interval between cabazitaxel-line use 9.5 6.9 7.2 8.6 Median in month (range) (2.3-56.0) (1.6-41.5) (3.7-20.6) Toxicity ≥ grade 3 (N) 5 5 5 5 5 5 5	[95% CI]	[44.5-NR]	[26.9-NR]	[13.7-NR]	[8.3-NR]			
Progression 0 1 (4.5) 10 (45) 1 (20) 0 Impaired ECOG PS 1 (4.5) 2 (9.1) 2 (9.1) 1 (20) 0 Toxicity 0 1 (4.5) 0 1 (20) 0 Free interval between cabazitaxel-line use 9.5 6.9 7.2 8.6 - Median in month (range) (2.3-56.0) (1.6-41.5) (3.7-20.6) - - Toxicity ≥grade 3 (N)	Reason for discontinuation, N (%)							
Impaired ECOG PS 1 (4.5) 2 (9.1) 1 (20) 0 Toxicity 0 1 (4.5) 0 1 (20) 0 Free interval between cabazitaxel-line use 9.5 6.9 7.2 8.6 Median in month (range) (2.3–56.0) (1.6–41.5) (3.7–20.6) Toxicity ≥grade 3 (N)	Predefined number of courses	21 (95.5)	18 (81.8)	10 (45)	2 (40)	1		
Toxicity 0 1 (4.5) 0 1 (20) 0 Free interval between cabazitaxel-line use 9.5 6.9 7.2 8.6 - Median in month (range) (2.3-56.0) (1.6-41.5) (3.7-20.6) - - Toxicity ≥grade 3 (N) - - - - -	Progression	0	1 (4.5)	10 (45)	1 (20)	0		
Free interval between cabazitaxel-line use9.56.97.28.6Median in month (range)(2.3-56.0)(1.6-41.5)(3.7-20.6)Toxicity ≥grade 3 (N)	Impaired ECOG PS	1 (4.5)	2 (9.1)	2 (9.1)	1 (20)	0		
cabazitaxel-line use (2.3-56.0) (1.6-41.5) (3.7-20.6) — — Toxicity ≥grade 3 (N) - <td< td=""><td>Toxicity</td><td>0</td><td>1 (4.5)</td><td>0</td><td>1 (20)</td><td>0</td></td<>	Toxicity	0	1 (4.5)	0	1 (20)	0		
Toxicity ≥grade 3 (N)		9.5	6.9	7.2	8.6	_		
	Median in month (range)	(2.3-56.0)	(1.6-41.5)	(3.7–20.6)	—	—		
Fatigue 2 0 0 0 0	Toxicity ≥grade 3 (N)							
	Fatigue	2	0	0	0	0		
Diarrhea 3 0 1 0 0	Diarrhea	3	0	1	0	0		
Hematuria 0 1 2 0 0	Hematuria	0	1	2	0	0		
Febrile neutropenia00100	Febrile neutropenia	0	0	1	0	0		
Cholestasis 0 1 0 0 0	Cholestasis	0	1	0	0	0		

Abbreviations: ECOG-PS, European Cooperative Oncology Group performance status; G-CSF, granulocyte-colony stimulating factor; NR, not reached; PFS, progression-free survival; PSA, prostate-specific antigen.

5 | CONCLUSION

In conclusion, our results suggest that, in heavily pretreated mCRPC patients, cabazitaxel can be rechallenged without cumulative toxicity in mCRPC patients with good initial response to cabazitaxel and still fit to receive it. In this selected population, cabazitaxel multiple rechallenges may also extend OS with no cumulative toxicity. Cabazitaxel rechallenge should thus be considered as a therapeutic option for such patients.

ETHICAL APPROVAL STATEMENT

This study received Ethics Committee approval. Patients still alive gave their written consent and confidentiality approval was obtained from the Commission Nationale de l'Informatique et des Libertés (CNIL).

AUTHOR CONTRIBUTIONS

Conception and design: Constance Thibault & Stéphane Oudard. Acquisition of data: Cedric Pobel, Diego Teyssonneau, Brigitte Laguerre, Mathilde Cancel, Elouen Boughalem, Johanna Noel, Pierre Emmanuel Brachet, Denis Maillet, Philippe Barthelemy, Carole Helissey. Statistical analysis and interpretation of data: Cedric Pobel & Edouard Auclin. Drafting of the manuscript: Cedric Pobel & Edouard Auclin. Critical revision of the manuscript for important intellectual content: Elouen Boughalem, Johanna Noel, Pierre Emmanuel Brachet, Denis Maillet, Philippe Barthelemy, Carole Helissey & Constance Thibault. Supervision: Constance Thibault & Stéphane Oudard.

CONFLICT OF INTEREST

The authors have no conflict of interest to declare.

DATA AVAILABILITY STATEMENT

The research data are available upon reasonable request to the corresponding author (cedric.pobel@gmail.com).

ORCID

Cedric Pobel D https://orcid.org/0000-0001-6251-622X Carole Helissey D https://orcid.org/0000-0002-7774-349X

REFERENCES

- 1. Nuhn P, De Bono JS, Fizazi K, et al. Update on systemic prostate cancer therapies: management of metastatic castrationresistant prostate cancer in the era of precision oncology. *Eur Urol.* 2019;75:88-99.
- de Bono J, Mateo J, Fizazi K, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382(22):2091-2102.
- 3. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. *Lancet.* 2010;376:1147-1154.
- Oudard S, Fizazi K, Sengeløv L, et al. Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized phase III trial-FIRSTANA. J Clin Oncol. 2017;35:3189-3197.
- Khalaf DJ, Annala M, Taavitsainen S, et al. Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre,

randomised, open-label, phase 2, crossover trial. *Lancet Oncol.* 2019;20:1730-1739.

- de Wit R, de Bono J, Sternberg CN, et al. Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N Engl J Med. 2019;381(26):2506-2518.
- van Soest RJ, de Morrée ES, Kweldam CF, et al. Targeting the androgen receptor confers in vivo cross-resistance between enzalutamide and docetaxel, but not cabazitaxel, in castrationresistant prostate cancer. *Eur Urol.* 2015;67:981-985.
- van Soest RJ, Nieuweboer AJM, de Morrée ES, et al. Dutch Uro-Oncology Studygroup (DUOS). The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer. *Eur J Cancer*. 2015;51:2562-2569.
- Delanoy N, Hardy-Bessard A-C, Efstathiou E, et al. Sequencing of taxanes and new androgen-targeted therapies in metastatic castrationresistant prostate cancer: results of the international multicentre retrospective CATS database. *Eur Urol Oncol.* 2018;1:467-475.
- Angelergues A, Efstathiou E, Gyftaki R, et al. Results of the FLAC European database of metastatic castration-resistant prostate cancer patients treated with docetaxel, cabazitaxel, and androgen receptor-targeted agents. *Clin Genitourin Cancer*. 2018;16:e777-e784.
- 11. Omlin A, Sartor O, Rothermundt C, et al. Analysis of side effect profile of alopecia, nail changes, peripheral neuropathy, and dysgeusia in prostate cancer patients treated with docetaxel and cabazitaxel. *Clin Genitourin Cancer*. 2015;13:e205-e208.
- 12. Thibault C, Eymard J-C, Birtle A, et al. Efficacy of cabazitaxel rechallenge in heavily treated patients with metastatic castrationresistant prostate cancer. *Eur J Cancer*. 2018;97:41-48.
- 13. Oudard S, Kramer G, Caffo O, et al. Docetaxel rechallenge after an initial good response in patients with metastatic castrationresistant prostate cancer. *BJU Int.* 2015;115:744-752.
- 14. Mout L, Moll JM, Chen M, et al. Androgen receptor signalling impairs docetaxel efficacy in castration-resistant prostate cancer. *Br J Cancer*. 2020;123(12):1715-1719.
- de Morrée E, van Soest R, Aghai A, et al. Understanding taxanes in prostate cancer; importance of intratumoral drug accumulation. *Prostate*. 2016;76:927-936.

How to cite this article: Pobel C, Auclin E, Teyssonneau D, et al. Cabazitaxel multiple rechallenges in metastatic castration-resistant prostate cancer. *Cancer Med.* 2021;10:6304–6309. https://doi.org/10.1002/cam4.4172

-WILEY